α5-integrin is crucial for L1CAM-mediated chemoresistance in pancreatic adenocarcinoma

International Journal of Oncology

Volumn 34, Issue 1, 2009, Pages 243-253

  Müerköster, Susanne Sebens ^a   Kötteritzsch, Jörn ^a   Geismann, Claudia ^a   Gast, Daniela ^b   Kruse, Marie Luise ^a   Altevogt, Peter ^b   Fölsch, Ulrich R ^a   Schäfer, Heiner ^a  

^a UNIVERSITY OF KIEL   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Caspases; Chemoresistance; Integrin; L1CAM; Pancreatic adenocarcinoma

Indexed keywords

ALPHA5 INTEGRIN; ANTINEOPLASTIC AGENT; CASPASE; CASPASE 3; CASPASE 7; CELL ADHESION MOLECULE; INDUCIBLE NITRIC OXIDE SYNTHASE; LIGAND; MUTANT PROTEIN; NITRIC OXIDE; ETOPOSIDE; MESSENGER RNA; NERVE CELL ADHESION MOLECULE L1; NOS2A PROTEIN, HUMAN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CANCER CELL CULTURE; CANCER RESISTANCE; CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME ACTIVATION; ENZYME INHIBITION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; ADENOCARCINOMA; APOPTOSIS; DRUG EFFECT; DRUG RESISTANCE; FLOW CYTOMETRY; GENETICS; METABOLISM; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SITE DIRECTED MUTAGENESIS; TUMOR CELL CULTURE; WESTERN BLOTTING;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, PANCREATIC DUCTAL; CASPASES; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; FLOW CYTOMETRY; HUMANS; INTEGRIN ALPHA5; MUTAGENESIS, SITE-DIRECTED; NEURAL CELL ADHESION MOLECULE L1; NITRIC OXIDE SYNTHASE TYPE II; PANCREATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 60749122433     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000146     Document Type: Article

References (39)

1. Fogel M, Gutwein P, Mechtersheimer S, Riedle S, Stoeck A, Smirnov A, Edler L, Ben-Arie A, Huszar M and Altevogt P: L1 adhesion molecule (CD 171) in development and progression of human malignant melanoma. Lancet 362: 869-875, 2003.
2. Gavert N, Conacci-Sorrell M, Gast D, Schneider A, Altevogt P, Brabletz T and Ben-Ze'ev A: L1, a novel target of beta-catenin signaling, transforms cells and is expressed at the invasive front of colon cancers. J Cell Biol 168: 633-642, 2005.
3. Kaifi JT, Reichelt U, Quaas A, Schurr PG, Wachowiak R, Yekebas EF, Strate T, Schneider C, Pantel K, Schachner M, Sauter G and Izbicki JR: L1 is associated with micrometastatic spread and poor outcome in colorectal cancer. Mod Pathol 20: 1183-1190, 2007.
4. Shtutman M, Levina E, Ohouo P, Baig M and Roninson IB: Cell adhesion molecule L1 disrupts E-cadherin-containing adherens junctions and increases scattering and motility of MCF7 breast carcinoma cells. Cancer Res 66: 11370-11380, 2006.
5. Thies A, Schachner M, Moll I, Berger J, Schulze HJ, Brunner G and Schumacher U: Overexpression of the cell adhesion molecule L1 is associated with metastasis in cutaneous malignant melanoma. Eur J Cancer 38: 1708-1716, 2002.
6. Sebens Muerkoster S, Werbing V, Sipos B, Debus MA, Witt M, Grossmann M, Leisner D, Kotteritzsch J, Kappes H, Kloppel G, Altevogt P, Folsch UR and Schafer H: Drug-induced expression of the cellular adhesion molecule L1CAM confers antiapoptotic protection and chemoresistance in pancreatic ductal adenocarcinoma cells. Oncogene 26: 2759-2768, 2007.
7. Moos M, Tacke R, Scherer H, Teplow D, Fruh K and Schachner M: Neural adhesion molecule L1 as a member of the immunoglobulin superfamily with binding domains similar to fibronectin. Nature 334: 701-703, 1998.
8. Castellani V, De Angelis E, Kenwrick S and Rougon G: Cis and trans interactions of L1 with neuropilin-1 control axonal responses to semaphorin 3A. EMBO J 21: 6348-6357, 2002.
9. Ebeling O, Duczmal A, Aigner S, Geiger C, Schollhammer S, Kemshead JT, Moller P, Schwartz-Albiez R and Altevogt P: L1 adhesion molecule on human lymphocytes and monocytes: expression and involvement in binding to alpha v beta 3 integrin. Eur J Immunol 26: 2508-2516, 1996.
10. Montgomery AM, Becker JC, Siu CH, Lemmon VP, Cheresh DA, Pancook JD, Zhao X and Reisfeld RA: Human neural cell adhesion molecule L1 and rat homologue NILE are ligands for integrin alpha v beta 3. J Cell Biol 132: 475-485, 1996.
11. Oleszewski M, Beer S, Katich S, Geiger C, Zeller Y, Rauch U and Altevogt P: Integrin and neurocan binding to L1 involves distinct Ig domains. J Biol Chem 274: 24602-24610, 1999.
12. Ruppert M, Aigner S, Hubbe M, Yagita H and Altevogt P: The L1 adhesion molecule is a cellular ligand for VLA-5. J Cell Biol 131: 1881-1891, 1995.
13. Stoeck A, Schlich S, Issa Y, Gschwend V, Wenger T, Herr I, Marme A, Bourbie S, Altevogt P and Gutwein P: L1 on ovarian carcinoma cells is a binding partner for Neuropilin-1 on mesothelial cells. Cancer Lett 239: 212-226, 2006.
14. Oleszewski M, Gutwein P, von der Lieth W, Rauch U and Altevogt P: Characterization of the L1-neurocan-binding site. Implications for L1-L1 homophilic binding. J Biol Chem 275: 34478-34485, 2000.
15. Gast D, Riedle S, Schabath H, Schlich S, Schneider A, Issa Y, Stoeck A, Fogel M, Joumaa S, Wenger T, Herr I, Gutwein P and Altevogt, P: L1 augments cell migration and tumor growth but not beta3 integrin expression in ovarian carcinomas. Int J Cancer 115: 658-665, 2005.
16. Mechtersheimer S, Gutwein P, Agmon-Levin N, Stoeck A, Oleszewski M, Riedle S, Postina R, Fahrenholz F, Fogel M, Lemmon V and Altevogt P: Ectodomain shedding of L1 adhesion molecule promotes cell migration by autocrine binding to integrins. J Cell Biol 155: 661-673, 2001.
17. Meier F, Busch S, Gast D, Goppert A, Altevogt P, Maczey E, Riedle S, Garbe C and Schittek B: The adhesion molecule L1 (CD171) promotes melanoma progression. Int J Cancer 119: 549-555, 2006.
18. Silletti S, Yebra M, Perez B, Cirulli V, McMahon M and Montgomery AM: Extracellular signal-regulated kinase (ERK)-dependent gene expression contributes to L1 cell adhesion molecule-dependent motility and invasion. J Biol Chem 279: 28880-28888, 2004.
19. Stoeck A, Gast D, Sanderson MP, Issa Y, Gutwein P and Altevogt P: L1-CAM in a membrane-bound or soluble form augments protection from apoptosis in ovarian carcinoma cells. Gynecol Oncol 104: 461-469, 2007.
20. Sebens Muerkoster S, Lust J, Arlt A, Hasler R, Witt M, Sebens T, Schreiber S, Folsch UR and Schafer H: Acquired chemoresistance in pancreatic carcinoma cells: induced secretion of IL-1beta and NO lead to inactivation of caspases. Oncogene 25: 3973-3981, 2006.
21. Arlt MJ, Novak-Hofer I, Gast D, Gschwend V, Moldenhauer G, Grunberg J, Honer M, Schubiger PA, Altevogt P and Kruger A: Efficient inhibition of intra-peritoneal tumor growth and dissemination of human ovarian carcinoma cells in nude mice by anti-L1-cell adhesion molecule monoclonal antibody treatment. Cancer Res 66: 936-943, 2006.
22. Knogler K, Grunberg J, Zimmermann K, Cohrs S, Honer M, Ametamey S, Altevogt P, Fogel M, Schubiger PA and Novak-Hofer I: Copper-67 radioimmunotherapy and growth inhibition by anti-L1-cell adhesion molecule monoclonal antibodies in a therapy model of ovarian cancer metastasis. Clin Cancer Res 13: 603-611, 2007.
23. Primiano T, Baig M, Maliyekkel A, Chang BD, Fellars S, Sadhu J, Axenovich SA, Holzmayer TA and Roninson IB: Identification of potential anticancer drug targets through the selection of growth-inhibitory genetic suppressor elements. Cancer Cell 4: 41-53, 2003.
24. Moore PS, Sipos B, Orlandini S, Sorio C, Real FX, Lemoine NR, Gress T, Bassi C, Kloppel G, Kalthoff H, Ungefroren H, Lohr M and Scarpa A: Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4. Virchows Arch 439: 798-802, 2001.
25. Gast D, Riedle S, Kiefel H, Sebens Muerkoster S, Schafer H, Schafer MKE and Altevogt P: The RGD integrin binding site in human L1-CAM is important for nuclear signaling. Exp Cell Res 314: 1053-1062, 2008.
26. Arlt A, Vorndamm J, Breitenbroich M, Folsch UR, Kalthoff H, Schmidt WE and Schafer H: Inhibition of NF-kappaB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin. Oncogene 20: 859-868, 2001.
27. Schafer H, Arlt A, Trauzold A, Hunermann-Jansen A and Schmidt WE: The putative apoptosis inhibitor IEX-1L is a mutant nonspliced variant of p22(PRG1/IEX-1) and is not expressed in vivo. Biochem Biophys Res Commun 262: 139-145, 1999.
28. Wey JS, Gray MJ, Fan F, Belcheva A, McCarty MF, Stoeltzing O, Somcio R, Liu W, Evans DB, Klagsbrun M, Gallick GE and Ellis LM: Overexpression of neuropilin-1 promotes constitutive MAPK signalling and chemoresistance in pancreatic cancer cells. Br J Cancer 93: 233-241, 2005.
29. Duczmal A, Schollhammer S, Katich S, Ebeling O, Schwartz-Albiez R and Altevogt P: The L1 adhesion molecule supports alpha v beta 3-mediated migration of human tumor cells and activated T lymphocytes. Biochem Biophys Res Commun 232: 236-239, 1997.
30. Friedl P, Hegerfeldt Y and Tusch M: Collective cell migration in morphogenesis and cancer. Int J Dev Biol 48: 441-449, 2004.
31. Hynes RO: Integrins: versatility, modulation, and signaling in cell adhesion. Cell 69: 11-25, 1992.
32. Estrugo D, Fischer A, Hess F, Scherthan H, Belka C and Cordes N: Ligand bound beta1 integrins inhibit procaspase-8 for mediating cell adhesion-mediated drug and radiation resistance in human leukemia cells. PLoS ONE 2: e269, 2007.
33. Miyamoto H, Murakami T, Tsuchida K, Sugino H, Miyake H and Tashiro S: Tumor-stroma interaction of human pancreatic cancer: acquired resistance to anticancer drugs and proliferation regulation is dependent on extracellular matrix proteins. Pancreas 28: 38-44, 2004.
34. Weekes CD, Kuszynski CA and Sharp JG: VLA-4 mediated adhesion to bone marrow stromal cells confers chemoresistance to adherent lymphoma cells. Leuk Lymphoma 40: 631-645, 2001.
35. Weinel RJ, Rosendahl A, Neumann K, Chaloupka B, Erb D, Rothmund M and Santoso S: Expression and function of VLA-alpha 2, -alpha 3, -alpha 5 and -alpha 6-integrin receptors in pancreatic carcinoma. Int J Cancer 52: 827-833, 1992.
36. Grzesiak JJ and Bouvet M: The alpha2beta1 integrin mediates the malignant phenotype on type I collagen in pancreatic cancer cell lines. Br J Cancer 94: 1311-1319, 2006.
37. Vogelmann R, Kreuser ED, Adler G and Lutz MP: Integrin alpha6beta1 role in metastatic behavior of human pancreatic carcinoma cells. Int J Cancer 80: 791-795, 1999.
38. Sawai H, Funahashi H, Matsuo Y, Yamamoto M, Okada Y, Hayakawa T and Manabe T: Expression and prognostic roles of integrins and interleukin-1 receptor type I in patients with ductal adenocarcinoma of the pancreas. Dig Dis Sci 48: 1241-1250, 2003.
39. Sawai H, Okada Y, Funahashi H, Matsuo Y, Takahashi H, Takeyama H and Manabe T: Interleukin-1alpha enhances the aggressive behavior of pancreatic cancer cells by regulating the alpha6beta1-integrin and urokinase plasminogen activator receptor expression. BMC Cell Biol 7: 8, 2006.